Limba
|
Sovleplenib(HMPL-523) is a highly potent and selective SYKinhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. Sovleplenib exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL).
Price | 2.345,00 RON (preturile sunt fara TVA) |
---|---|
Description |
Sovleplenib(HMPL-523) is a highly potent and selective SYKinhibitor with IC50 of 0.025 μM, that exhibits anti-tumor activities in vitro and in vivo. Sovleplenib exhibits synergistic activities in combination with BTK, PI3Kδ, and Bcl2 family inhibitors in killing human-diffused large B cell lymphoma (DLBCL). |